Latest Breaking News On - உலகளாவிய ஒழுங்குமுறை வாழ்க்கைத்தொழில்கள் இல் அலெக்சியன் மருந்துகள் - Page 1 : comparemela.com
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Gain Therapeutics
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.
(2)
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. ( Gain ) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board. We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain, said Eric Richman, Chief Executive Officer at Gain. Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Therapy (Se